A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes

Keyphrases

• Autoimmune Disease 33%
• Base Editor 33%
• Cancer Cells 33%
• Cas9 Protein 66%
• Cas9 RNP 33%
• Cellular Immunotherapy 33%
• Chemokine Receptor 33%
• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 100%
• Dendritic Cell Subsets 33%
• Donor Template 33%
• Downstream Effectors 33%
• Effector Cells 33%
• Enhanced Activity 33%
• Gene Knockout 33%
• Genetic Engineering 66%
• Innate Immune Response 33%
• Knock 33%
• Macrophage Cells 33%
• Monocyte-derived Macrophages 33%
• Monocytes 100%
• MRNA Expression 33%
• Primary Monocytes 100%
• Recombinant Adeno-associated Virus (rAAV) 33%
• Ribonuclease 33%
• RNase Inhibitor 100%
• Signal Regulatory Protein α (SIRPα) 33%
• Tissue Homeostasis 33%
• Translational Research 33%

Immunology and Microbiology

• Autoimmune Disease 50%
• Cancer Cell 50%
• Chemokine Receptor 50%
• Clustered Regularly Interspaced Short Palindromic Repeat 100%
• CRISPR/Cas9 100%
• Dendritic Cell Subset 50%
• DNA Template 50%
• DNA Vector 50%
• Effector Cell 50%
• Gene Knockout 50%
• Gene Targeting 50%
• Genome Editing 100%
• Homeostasis 50%
• Immunotherapy 50%
• Innate Immune System 50%
• Macrophage 100%
• Transgene 50%

Biochemistry, Genetics and Molecular Biology

• Cancer Cell 33%
• Cas9 33%
• Chemokine Receptor 33%
• CRISPR 100%
• CRISPR/Cas9 66%
• Dendritic Cell 33%
• DNA Template 33%
• DNA Vector 33%
• Enzyme 33%
• Gene Knockout 33%
• Gene Targeting 33%
• Genome Editing 66%
• Homeostasis 33%
• Innate Immunity 33%
• Macrophage 66%
• Messenger RNA 100%
• Ribonuclease Inhibitor 100%
• Ribonucleoprotein 33%
• Transgene 33%